Literature DB >> 22453023

Treatment of melanoma brain metastases: a new paradigm.

Matteo S Carlino1, Gerald B Fogarty, Georgina V Long.   

Abstract

Brain metastases occur commonly in patients with metastatic melanoma, are associated with a poor prognosis, and cause significant morbidity. Both surgery and stereotactic radiosurgery are used to control brain metastases and, in selected patients, improve survival. In those with extensive brain involvement, whole-brain radiotherapy can alleviate symptoms. Historically, systemic therapy has had little role to play in the management of melanoma brain metastases; however, early clinical trials of BRAF inhibitors have shown promising activity. This review examines the evidence for local and systemic treatments in the management of patients with melanoma brain metastases. We present a new treatment algorithm for melanoma patients with brain metastases, which integrates the evolving evidence for the use of BRAF inhibitors.

Entities:  

Mesh:

Year:  2012        PMID: 22453023     DOI: 10.1097/PPO.0b013e31824b2890

Source DB:  PubMed          Journal:  Cancer J        ISSN: 1528-9117            Impact factor:   3.360


  14 in total

1.  Lassa-vesicular stomatitis chimeric virus safely destroys brain tumors.

Authors:  Guido Wollmann; Eugene Drokhlyansky; John N Davis; Connie Cepko; Anthony N van den Pol
Journal:  J Virol       Date:  2015-04-15       Impact factor: 5.103

2.  A phase 2 trial of stereotactic radiosurgery boost after surgical resection for brain metastases.

Authors:  Cameron Brennan; T Jonathan Yang; Patrick Hilden; Zhigang Zhang; Kelvin Chan; Yoshiya Yamada; Timothy A Chan; Stella C Lymberis; Ashwatha Narayana; Viviane Tabar; Philip H Gutin; Åse Ballangrud; Eric Lis; Kathryn Beal
Journal:  Int J Radiat Oncol Biol Phys       Date:  2014-01-01       Impact factor: 7.038

Review 3.  Managing leptomeningeal melanoma metastases in the era of immune and targeted therapy.

Authors:  Keiran S M Smalley; Inna V Fedorenko; Rajappa S Kenchappa; Solmaz Sahebjam; Peter A Forsyth
Journal:  Int J Cancer       Date:  2016-04-30       Impact factor: 7.396

Review 4.  Current treatment options of brain metastases and outcomes in patients with malignant melanoma.

Authors:  Jadwiga Nowak-Sadzikowska; Tomasz Walasek; Jerzy Jakubowicz; Paweł Blecharz; Marian Reinfuss
Journal:  Rep Pract Oncol Radiother       Date:  2015-12-29

5.  Vesicular stomatitis virus variants selectively infect and kill human melanomas but not normal melanocytes.

Authors:  Guido Wollmann; John N Davis; Marcus W Bosenberg; Anthony N van den Pol
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

6.  Detection and quantification of CSF malignant cells by the CellSearch technology in patients with melanoma leptomeningeal metastasis.

Authors:  Emilie Le Rhun; Qian Tu; Marcelo De Carvalho Bittencourt; Isabelle Farre; Laurent Mortier; Huili Cai; Chantal Kohler; Gilbert C Faure
Journal:  Med Oncol       Date:  2013-03-16       Impact factor: 3.064

7.  Melanoma brain metastases: the impact of nodal disease.

Authors:  James E Jackson; Bryan H Burmeister; Elizabeth A Burmeister; Matthew C Foote; Janine M Thomas; Janelle A Meakin; B Mark Smithers
Journal:  Clin Exp Metastasis       Date:  2013-08-23       Impact factor: 5.150

8.  The role of whole brain radiation therapy in the management of melanoma brain metastases.

Authors:  Michael A Dyer; Nils D Arvold; Yu-Hui Chen; Nancy E Pinnell; Timur Mitin; Eudocia Q Lee; F Stephen Hodi; Nageatte Ibrahim; Stephanie E Weiss; Paul J Kelly; Scott R Floyd; Anand Mahadevan; Brian M Alexander
Journal:  Radiat Oncol       Date:  2014-06-22       Impact factor: 3.481

Review 9.  Dabrafenib and its potential for the treatment of metastatic melanoma.

Authors:  Alexander M Menzies; Georgina V Long; Rajmohan Murali
Journal:  Drug Des Devel Ther       Date:  2012-12-11       Impact factor: 4.162

10.  Innovative therapeutic strategies in the treatment of brain metastases.

Authors:  Maria Caffo; Valeria Barresi; Gerardo Caruso; Mariano Cutugno; Giuseppe La Fata; Mario Venza; Concetta Alafaci; Francesco Tomasello
Journal:  Int J Mol Sci       Date:  2013-01-22       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.